
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).
EO2463 plus R2 was well tolerated in patients with...